Does the media prefer SLN or BEAM?

In the previous week, Beam Therapeutics had 5 more articles in the media than Silence Therapeutics. MarketBeat recorded 6 mentions for Beam Therapeutics and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.78 beat Beam Therapeutics' score of 0.23 indicating that Silence Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SLN or IRON?

In the previous week, Disc Medicine had 4 more articles in the media than Silence Therapeutics. MarketBeat recorded 5 mentions for Disc Medicine and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.78 beat Disc Medicine's score of 0.41 indicating that Silence Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Disc Medicine 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IMNM or SLN?

In the previous week, Immunome had 10 more articles in the media than Silence Therapeutics. MarketBeat recorded 11 mentions for Immunome and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.78 beat Immunome's score of 0.62 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 3 Very Positive mention(s) 5 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CLDX or SLN?

In the previous week, Celldex Therapeutics had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 3 mentions for Celldex Therapeutics and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.78 beat Celldex Therapeutics' score of 0.18 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NRIX or SLN?

In the previous week, Nurix Therapeutics had 7 more articles in the media than Silence Therapeutics. MarketBeat recorded 8 mentions for Nurix Therapeutics and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.78 beat Nurix Therapeutics' score of 0.29 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Silence Therapeutics (SLN) Competitors

$10.64 -0.07 (-0.65%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$10.66 +0.01 (+0.14%)

As of 10/2/2026 07:30 PM Eastern

Compare

SLN vs. BEAM, IRON, IMNM, CLDX, and NRIX

Should you buy Silence Therapeutics stock or one of its competitors? Silence Therapeutics's main competitors and comparable companies include Beam Therapeutics (BEAM), Disc Medicine (IRON), Immunome (IMNM), Celldex Therapeutics (CLDX), and Nurix Therapeutics (NRIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Silence Therapeutics compare to Beam Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Silence Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.2, suggesting that its share price is 120% more volatile than the broader market.

Beam Therapeutics has a net margin of -54.75% compared to Silence Therapeutics' net margin of -8,943.86%. Beam Therapeutics' return on equity of -30.71% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

In the previous week, Beam Therapeutics had 5 more articles in the media than Silence Therapeutics. MarketBeat recorded 6 mentions for Beam Therapeutics and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.78 beat Beam Therapeutics' score of 0.23 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Silence Therapeutics currently has a consensus price target of $53.50, suggesting a potential upside of 402.82%. Beam Therapeutics has a consensus price target of $49.00, suggesting a potential upside of 100.00%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Beam Therapeutics has higher revenue and earnings than Silence Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	1,143.99	-$88.61M	-$1.28	N/A
Beam Therapeutics	$139.74M	18.11	-$79.99M	-$0.86	N/A

Summary

Beam Therapeutics beats Silence Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Silence Therapeutics compare to Disc Medicine?

Silence Therapeutics (NASDAQ:SLN) and Disc Medicine (NASDAQ:IRON) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

In the previous week, Disc Medicine had 4 more articles in the media than Silence Therapeutics. MarketBeat recorded 5 mentions for Disc Medicine and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.78 beat Disc Medicine's score of 0.41 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Disc Medicine	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Disc Medicine has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Disc Medicine's return on equity of -37.17% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%
Disc Medicine	N/A	-37.17%	-33.65%

Silence Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Comparatively, 3.8% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Silence Therapeutics has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	1,143.99	-$88.61M	-$1.28	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

Silence Therapeutics presently has a consensus target price of $53.50, suggesting a potential upside of 402.82%. Disc Medicine has a consensus target price of $110.18, suggesting a potential upside of 70.80%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Silence Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Summary

Silence Therapeutics beats Disc Medicine on 10 of the 16 factors compared between the two stocks.

How does Silence Therapeutics compare to Immunome?

Immunome (NASDAQ:IMNM) and Silence Therapeutics (NASDAQ:SLN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Immunome has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Immunome's return on equity of -50.56% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%

44.6% of Immunome shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 7.2% of Immunome shares are held by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Immunome has a beta of 2.55, meaning that its stock price is 155% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

Silence Therapeutics has lower revenue, but higher earnings than Immunome. Silence Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	342.05	-$212.39M	-$2.53	N/A
Silence Therapeutics	$560K	1,143.99	-$88.61M	-$1.28	N/A

Immunome currently has a consensus target price of $34.25, suggesting a potential upside of 63.88%. Silence Therapeutics has a consensus target price of $53.50, suggesting a potential upside of 402.82%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Silence Therapeutics is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Immunome had 10 more articles in the media than Silence Therapeutics. MarketBeat recorded 11 mentions for Immunome and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.78 beat Immunome's score of 0.62 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	3 Very Positive mention(s)	5 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immunome beats Silence Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Silence Therapeutics compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Silence Therapeutics (NASDAQ:SLN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

In the previous week, Celldex Therapeutics had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 3 mentions for Celldex Therapeutics and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.78 beat Celldex Therapeutics' score of 0.18 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celldex Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Celldex Therapeutics' return on equity of -52.35% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.35%	-47.61%
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%

Celldex Therapeutics presently has a consensus price target of $61.92, suggesting a potential upside of 95.65%. Silence Therapeutics has a consensus price target of $53.50, suggesting a potential upside of 402.82%. Given Silence Therapeutics' higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Silence Therapeutics has lower revenue, but higher earnings than Celldex Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,613.94	-$258.76M	-$4.35	N/A
Silence Therapeutics	$560K	1,143.99	-$88.61M	-$1.28	N/A

Celldex Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

98.7% of Silence Therapeutics shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Celldex Therapeutics beats Silence Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Silence Therapeutics compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Silence Therapeutics (NASDAQ:SLN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

Nurix Therapeutics has a net margin of -928.44% compared to Silence Therapeutics' net margin of -8,943.86%. Nurix Therapeutics' return on equity of -76.09% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%

Silence Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	28.41	-$264.46M	-$3.45	N/A
Silence Therapeutics	$560K	1,143.99	-$88.61M	-$1.28	N/A

Nurix Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

98.7% of Silence Therapeutics shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nurix Therapeutics currently has a consensus target price of $34.21, suggesting a potential upside of 48.82%. Silence Therapeutics has a consensus target price of $53.50, suggesting a potential upside of 402.82%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Silence Therapeutics is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Nurix Therapeutics had 7 more articles in the media than Silence Therapeutics. MarketBeat recorded 8 mentions for Nurix Therapeutics and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.78 beat Nurix Therapeutics' score of 0.29 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Silence Therapeutics beats Nurix Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Silence Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLN vs. The Competition

Export

Metric	Silence Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$640.62M	$3.87B	$7.14B	$13.22B
Dividend Yield	N/A	3.64%	2.53%	16.78%
P/E Ratio	-8.31	13.13	275.97	26.04
Price / Sales	1,041.66	1,434.36	672.88	109.45
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	8.06	16.63	10.93	6.31
Net Income	-$88.61M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-4.83%	-2.99%	-2.00%	-1.66%
1 Month Performance	-28.06%	-10.60%	-6.15%	-4.50%
1 Year Performance	112.80%	19.44%	7.44%	2.06%

Silence Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLN Silence Therapeutics	2.5465 of 5 stars	$10.64 -0.7%	$53.50 +402.8%	+104.6%	$640.62M	$615K	N/A	88
BEAM Beam Therapeutics	2.6007 of 5 stars	$24.52 +1.2%	$49.00 +99.8%	-4.3%	$2.53B	$139.74M	N/A	540	Analyst Upgrade Gap Up
IRON Disc Medicine	2.5314 of 5 stars	$65.87 +1.5%	$110.18 +67.3%	-2.0%	$2.53B	N/A	N/A	165
IMNM Immunome	2.6458 of 5 stars	$21.89 +1.0%	$35.18 +60.7%	+82.2%	$2.49B	$6.94M	N/A	177	News Coverage Analyst Forecast Gap Up
CLDX Celldex Therapeutics	2.028 of 5 stars	$31.64 +0.5%	$61.92 +95.7%	+22.4%	$2.48B	$1.54M	N/A	198	Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLN) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silence Therapeutics (SLN) Competitors

SLN vs. BEAM, IRON, IMNM, CLDX, and NRIX

How does Silence Therapeutics compare to Beam Therapeutics?

Summary

How does Silence Therapeutics compare to Disc Medicine?

Summary

How does Silence Therapeutics compare to Immunome?

Summary

How does Silence Therapeutics compare to Celldex Therapeutics?

Summary

How does Silence Therapeutics compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN vs. The Competition

Silence Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silence Therapeutics (SLN) Competitors

SLN vs. BEAM, IRON, IMNM, CLDX, and NRIX

How does Silence Therapeutics compare to Beam Therapeutics?

Which has more volatility and risk, SLN or BEAM?

Is SLN or BEAM more profitable?

Does the media prefer SLN or BEAM?

Do analysts prefer SLN or BEAM?

Do insiders and institutionals have more ownership in SLN or BEAM?

Which has better valuation & earnings, SLN or BEAM?

Summary

How does Silence Therapeutics compare to Disc Medicine?

Does the media prefer SLN or IRON?

Is SLN or IRON more profitable?

Which has more risk & volatility, SLN or IRON?

Do institutionals & insiders have more ownership in SLN or IRON?

Which has higher earnings and valuation, SLN or IRON?

Do analysts prefer SLN or IRON?

Summary

How does Silence Therapeutics compare to Immunome?

Is IMNM or SLN more profitable?

Do insiders & institutionals hold more shares of IMNM or SLN?

Which has more volatility and risk, IMNM or SLN?

Which has better earnings and valuation, IMNM or SLN?

Do analysts recommend IMNM or SLN?

Does the media prefer IMNM or SLN?

Summary

How does Silence Therapeutics compare to Celldex Therapeutics?

Does the media refer more to CLDX or SLN?

Is CLDX or SLN more profitable?

Do analysts recommend CLDX or SLN?

Which has higher earnings & valuation, CLDX or SLN?

Which has more risk and volatility, CLDX or SLN?

Do insiders & institutionals hold more shares of CLDX or SLN?

Summary

How does Silence Therapeutics compare to Nurix Therapeutics?

Is NRIX or SLN more profitable?

Which has preferable valuation & earnings, NRIX or SLN?

Which has more risk & volatility, NRIX or SLN?

Do institutionals and insiders hold more shares of NRIX or SLN?

Do analysts prefer NRIX or SLN?

Does the media refer more to NRIX or SLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN vs. The Competition

Silence Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools